Type of Vector | Structure of Base Vector Material | Target miR | Therapeutic Purpose | Target Disease | References | ||
---|---|---|---|---|---|---|---|
Antisense modified oligonucleotides | 2′-O-Me | miR-122 | Antisense | Liver disease | Krützfeldt et al., 2005 | ||
2′-F | miR-122 | Antisense | Liver disease | Davis et al., 2009 | |||
LNA | miR-122 | Antisense | Liver disease | Elmen et al., 2008 | |||
miR-122 | Antisense | HCV | Lanford et al., 2010 | ||||
miR-21 | Antisense | Glioma | Griveau et al., 2013 | ||||
miR-221 | Antisense | MM | Di Martino et al., 2014 | ||||
PNA | miR-155 | Antisense | Primary B cells | Fabani et al., 2010 | |||
Viral vectors | Lentiviruses | miR-146a | Overexpression | Diabetes | Zhuang et al., 2017 | ||
miR-199a | Overexpression | HCC | Jia et al., 2012 | ||||
Let-7 | Overexpression | NSCLC | Trang et al., 2010 | ||||
miR-15a/16 | Overexpression | CLL | Kasar et al., 2012 | ||||
AAV | miR-221 | Inhibition | HCC | Moshiri et al., 2014 | |||
miR-26a | Overexpression | HCC | Kota et al., 2009 | ||||
Nonviral vectors | Lipids | Cationic | DOTMA:cholesterol:TPGS | miR-29b | Mimic | NSCLC | Wu et al., 2013 |
DDAB:cholesterol:TPGS | miR-107 | Mimic | HNSCC | Piao et al., 2012 | |||
Anionic | DOPE:linoleic acid:DMG-PEG | miR-29b | Mimic | AML | Huang et al., 2013 | ||
Neutral | MaxSuppressor© (1,2-dioleoyl-sn-glycero-3-phosphocholine, squalene oil, polysorbate 20) | miR-34a, let-7 | Mimic | NSCLC | Trang et al., 2011 | ||
miR-34a | mimic | DLBCL | Craig et al., 2012 | ||||
Polymer | PEI | miR-145 | Mimic | CRC | Ibrahim et al., 2011 | ||
miR-33a | |||||||
miR-145 | Mimic | GBM | Yang et al., 2012 | ||||
miR-145 | Mimic | NSCLC | Chiou et al., 2012 | ||||
miR-135 | Mimic | GBM | Liang et al., 2017 | ||||
PLGA | miR-21 | Antisense | TNBC | Devulapally et al., 2015 | |||
miR-10b | |||||||
miR-34a | Mimic | MM | Cosco et al., 2015 | ||||
miR-99a | Mimic | HCC | Cai et al., 2017 | ||||
miR-204 | Mimic | CRC | Zheng et al., 2018 | ||||
Dendrimer/PAMAM | miR-21 | Antisense | BC | Ren et al., 2016 | |||
Chitosan | miR-34a | Mimic | Prostate cancer | Gaur et al., 2015 | |||
Liposomes | miR-101 | Mimic | HCC | Xu et al., 2017 | |||
Exosomes | miR-124a | Mimic | Glioma | Lang et al., 2018 | |||
Inorganic | Gold nanoparticle | miR-29b | Antisense | CC | Kim et al., 2011 | ||
miR-375 | Mimic | HCC | Xue et al., 2016 | ||||
miR-145 | Mimic | BC | Ekin et al., 2014 | ||||
Magnetic nanoparticle | Let-7 | Mimic | GBM | Yin et al., 2014a | |||
miR-145 | Mimic | PC | Setua et al., 2017 | ||||
miR-16 | Mimic | GC | Sun et al., 2014 | ||||
Diamond nanoparticle | miR-203 | Mimic | EC | Cao et al., 2013 | |||
Nucleic acid nanoparticle | RNA nanoparticle | miR-21 | Antisense | TNBC | Shu et al., 2015 | ||
miR-21 | Antisense | GBM | Lee et al., 2017 |
BC, breast cancer; CC, cervical cancer; DDAB, dimethyl dioctadecyl ammonium bromide; DMG, dimyristolglycerol; DOPE, dioleoylphosphatidylethanolamine; DOTMA, 1,2-di-O-octadecenyl-3-trimethylammonium propane; EC, esophageal cancer; GBM, glioblastoma; GC, gastric cancer; HNSCC, head and neck squamous cell carcinoma; MM, multiple myeloma; PAMAM, polyamidoamine; PC, pancreatic cancer; PEG, polyethylene glycol; PNA, peptide nucleic acids; TPGS, α-tocopheryl polyethylene glycol 1000 succinate; 2′-O-Me, 2′-O-methylation.